As Tregalizumab interacts with CD4+ CD25+ Tregs,31 which secrete high amounts of Trx1, it can be speculated that Trx1 might also negatively impact the binding and signalling of Tregalizumab in the synovium of RA patients. The gene discussed is CD4; the disease is rheumatoid arthritis.